Off-the-shelf approaches keep cell therapy investors keen
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Go or no go? Roche, Jazz and Camarus await crucial regulatory readouts
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
Old snafus come back to haunt Epizyme and Clovis
Two oncology specialists, Epizyme and Clovis, have been punished for ongoing problems.
Shikeda masks slow second quarter for buyouts
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
